- Home
- SGMO vs ENTX Comparison
SGMO vs ENTX Comparison
Compare SGMO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- ENTX
- Stock Information
- Founded
- SGMO 1995
- ENTX 2010
- Country
- SGMO United States
- ENTX Israel
- Employees
- SGMO N/A
- ENTX N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SGMO Health Care
- ENTX Health Care
- Exchange
- SGMO Nasdaq
- ENTX Nasdaq
- Market Cap
- SGMO 122.8M
- ENTX 142.0M
- IPO Year
- SGMO 2000
- ENTX 2018
- Fundamental
- Price
- SGMO $0.45
- ENTX $2.67
- Analyst Decision
- SGMO Buy
- ENTX Strong Buy
- Analyst Count
- SGMO 7
- ENTX 1
- Target Price
- SGMO $4.71
- ENTX $10.00
- AVG Volume (30 Days)
- SGMO 4.6M
- ENTX 256.6K
- Earning Date
- SGMO 11-06-2025
- ENTX 11-14-2025
- Dividend Yield
- SGMO N/A
- ENTX N/A
- EPS Growth
- SGMO N/A
- ENTX N/A
- EPS
- SGMO N/A
- ENTX N/A
- Revenue
- SGMO $32,875,000.00
- ENTX $166,000.00
- Revenue This Year
- SGMO $28.47
- ENTX N/A
- Revenue Next Year
- SGMO N/A
- ENTX N/A
- P/E Ratio
- SGMO N/A
- ENTX N/A
- Revenue Growth
- SGMO N/A
- ENTX 191.23
- 52 Week Low
- SGMO $0.41
- ENTX $1.50
- 52 Week High
- SGMO $2.84
- ENTX $3.22
- Technical
- Relative Strength Index (RSI)
- SGMO 29.91
- ENTX 53.03
- Support Level
- SGMO $0.42
- ENTX $2.61
- Resistance Level
- SGMO $0.53
- ENTX $3.22
- Average True Range (ATR)
- SGMO 0.04
- ENTX 0.25
- MACD
- SGMO -0.01
- ENTX -0.03
- Stochastic Oscillator
- SGMO 11.96
- ENTX 47.26
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.